These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 23648668)

  • 1. SETBP1 mutation analysis in 944 patients with MDS and AML.
    Thol F; Suchanek KJ; Koenecke C; Stadler M; Platzbecker U; Thiede C; Schroeder T; Kobbe G; Kade S; Löffeld P; Banihosseini S; Bug G; Ottmann O; Hofmann WK; Krauter J; Kröger N; Ganser A; Heuser M
    Leukemia; 2013 Oct; 27(10):2072-5. PubMed ID: 23648668
    [No Abstract]   [Full Text] [Related]  

  • 2. Analysis of NUP98/NSD1 translocations in adult AML and MDS patients.
    Thol F; Kölking B; Hollink IH; Damm F; van den Heuvel-Eibrink MM; Michel Zwaan C; Bug G; Ottmann O; Wagner K; Morgan M; Hofmann WK; Göhring G; Schlegelberger B; Krauter J; Ganser A; Heuser M
    Leukemia; 2013 Mar; 27(3):750-4. PubMed ID: 22929522
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical implications of the SETBP1 mutation in patients with primary myelodysplastic syndrome and its stability during disease progression.
    Hou HA; Kuo YY; Tang JL; Chou WC; Yao M; Lai YJ; Lin CC; Chen CY; Liu CY; Tseng MH; Huang CF; Chiang YC; Lee FY; Liu MC; Liu CW; Huang SY; Ko BS; Wu SJ; Tsay W; Chen YC; Tien HF
    Am J Hematol; 2014 Feb; 89(2):181-6. PubMed ID: 24127063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias.
    Damm F; Itzykson R; Kosmider O; Droin N; Renneville A; Chesnais V; Gelsi-Boyer V; de Botton S; Vey N; Preudhomme C; Clavert A; Delabesse E; Park S; Birnbaum D; Fontenay M; Bernard OA; Solary E
    Leukemia; 2013 Jun; 27(6):1401-3. PubMed ID: 23443343
    [No Abstract]   [Full Text] [Related]  

  • 5. Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms.
    Schnittger S; Bacher U; Haferlach C; Alpermann T; Dicker F; Sundermann J; Kern W; Haferlach T
    Leukemia; 2011 Apr; 25(4):615-21. PubMed ID: 21233837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FLT3 and NPM1 mutations in myelodysplastic syndromes: Frequency and potential value for predicting progression to acute myeloid leukemia.
    Bains A; Luthra R; Medeiros LJ; Zuo Z
    Am J Clin Pathol; 2011 Jan; 135(1):62-9. PubMed ID: 21173125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SETBP1 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.
    Yao XY; Zhou JD; Yang J; Zhang W; Ma JC; Wen XM; Yao DM; Xu ZJ; Wu DH; He PF; Qian J; Lin J
    Pathol Res Pract; 2018 May; 214(5):706-712. PubMed ID: 29549983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SETBP1 mutations in juvenile myelomonocytic leukaemia and myelodysplastic syndrome but not in paediatric acute myeloid leukaemia.
    Shiba N; Ohki K; Park MJ; Sotomatsu M; Kudo K; Ito E; Sako M; Arakawa H; Hayashi Y
    Br J Haematol; 2014 Jan; 164(1):156-9. PubMed ID: 24117422
    [No Abstract]   [Full Text] [Related]  

  • 9. Prognosis in patients with MDS or AML and bone marrow blasts between 10% and 30% is not associated with blast counts but depends on cytogenetic and molecular genetic characteristics.
    Bacher U; Kern W; Alpermann T; Schnittger S; Kohlmann A; Klein HU; Dugas M; Haferlach C; Haferlach T
    Leukemia; 2011 Aug; 25(8):1361-4. PubMed ID: 21494258
    [No Abstract]   [Full Text] [Related]  

  • 10. SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS.
    Inoue D; Kitaura J; Matsui H; Hou HA; Chou WC; Nagamachi A; Kawabata KC; Togami K; Nagase R; Horikawa S; Saika M; Micol JB; Hayashi Y; Harada Y; Harada H; Inaba T; Tien HF; Abdel-Wahab O; Kitamura T
    Leukemia; 2015 Apr; 29(4):847-57. PubMed ID: 25306901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events.
    Haferlach C; Bacher U; Schnittger S; Alpermann T; Zenger M; Kern W; Haferlach T
    Genes Chromosomes Cancer; 2012 Apr; 51(4):328-37. PubMed ID: 22162288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Study of nucleophosmin (NPM) gene mutation in patients with acute myeloid leukemia and myelodysplastic syndromes].
    Zhang Y; Zhang MR; Yang L; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2006 Jul; 27(7):470-3. PubMed ID: 17147251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome.
    Schnittger S; Eder C; Jeromin S; Alpermann T; Fasan A; Grossmann V; Kohlmann A; Illig T; Klopp N; Wichmann HE; Kreuzer KA; Schmid C; Staib P; Peceny R; Schmitz N; Kern W; Haferlach C; Haferlach T
    Leukemia; 2013 Jan; 27(1):82-91. PubMed ID: 23018865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of myelodysplasia-related changes according to the WHO classification among ELN-intermediate-risk AML patients.
    Devillier R; Gelsi-Boyer V; Murati A; Prebet T; Rey J; Etienne A; D'Incan E; Charbonnier A; Blaise D; Mozziconacci MJ; Vey N
    Am J Hematol; 2015 Jan; 90(1):E22-4. PubMed ID: 25219760
    [No Abstract]   [Full Text] [Related]  

  • 15. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations.
    Meggendorfer M; Bacher U; Alpermann T; Haferlach C; Kern W; Gambacorti-Passerini C; Haferlach T; Schnittger S
    Leukemia; 2013 Sep; 27(9):1852-60. PubMed ID: 23628959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS.
    Kanagal-Shamanna R; Luthra R; Yin CC; Patel KP; Takahashi K; Lu X; Lee J; Zhao C; Stingo F; Zuo Z; Routbort MJ; Singh RR; Fox P; Ravandi F; Garcia-Manero G; Medeiros LJ; Bueso-Ramos CE
    Oncotarget; 2016 Mar; 7(12):14251-8. PubMed ID: 26883102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. U2AF1 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.
    Qian J; Yao DM; Lin J; Qian W; Wang CZ; Chai HY; Yang J; Li Y; Deng ZQ; Ma JC; Chen XX
    PLoS One; 2012; 7(9):e45760. PubMed ID: 23029227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations in SETBP1 are recurrent in myelodysplastic syndromes and often coexist with cytogenetic markers associated with disease progression.
    Fernandez-Mercado M; Pellagatti A; Di Genua C; Larrayoz MJ; Winkelmann N; Aranaz P; Burns A; Schuh A; Calasanz MJ; Cross NC; Boultwood J
    Br J Haematol; 2013 Oct; 163(2):235-9. PubMed ID: 23889083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic Factors in Acute Myeloid Leukemia With Myelodysplasia-Related Changes.
    Fang H; He R; Chiu A; Viswanatha DS; Ketterling RP; Patnaik MS; Reichard KK
    Am J Clin Pathol; 2020 Apr; 153(5):656-663. PubMed ID: 31977035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NPM1 mutations in myelodysplastic syndromes and acute myeloid leukemia with normal karyotype.
    Zhang Y; Zhang M; Yang L; Xiao Z
    Leuk Res; 2007 Jan; 31(1):109-11. PubMed ID: 16678898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.